3상모집 중단 (진행 중)

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

연구 개요

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

스폰서
리드: 다케다
적응증
Plaque Psoriasis
중재
TAK-279
목표 등록
2,099
시작일
2024-09-04
완료(예정)
2029-08-05

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.